Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MMP13 | P45452 | 1/20 | 0.51 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | SMYD3 | Q9H7B4 | 11/20 | 0.47 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3195105 | 0.85 | CRBN (0.68) | CRBNSMYD3HDAC3 | |
| SCHEMBL11089929 | 0.78 | EIF2AK2 (0.63) | EIF2AK2 | |
| SCHEMBL11089100 | 0.76 | AHR (0.68) | SMN1; SMN2EIF2AK2 | |
| SCHEMBL5638486 | 0.76 | EIF2AK2 (0.61) | CRBNTSHRSMN1; SMN2EIF2AK2HDAC3 | |
| SCHEMBL5316057 | 0.76 | CRBN (0.81) | CRBNEIF2AK2SMYD3HDAC3 | |
| SCHEMBL23175457 | 0.76 | CRBN (1.00) | CRBNEIF2AK2SMYD3 | |
| SCHEMBL29899649 | 0.76 | CRBN (1.00) | CRBNEIF2AK2SMYD3 | |
| SCHEMBL13184545 | 0.75 | HPGD (1.00) | HPGDTSHRHTTSMN1; SMN2MMP13 | |
| SCHEMBL6980695 | 0.74 | GAA (0.48) | CRBNEIF2AK2SMYD3 | |
| SCHEMBL5638300 | 0.74 | SMYD3 (0.49) | HPGDTSHRSMN1; SMN2EIF2AK2SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787802-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787802-B2 | Dihydrobenzimidazolones for medical treatment | CRBN, CUL4A, ADRM1 | CRBN 1/4885HPGD 3006/4885TSHR 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.